schizophrenia

green light go go ahead advance yes streetlight

Pharma

FDA signs off on Vanda's Bysanti for schizophrenia and bipolar I

The FDA has approved Vanda's Bysanti as a first-line treatment for schizophrenia or for manic or mixed episodes associated with bipolar I disorder.

Kevin Dunleavy Feb 23, 2026 11:35am

Bristol Myers Squibb Cobenfy ad

BMS' Cobenfy TV ad is latest target of FDA untitled letter spree

Dec 19, 2025 10:44am

Bristol Myers Squibb Cobenfy Connections Gail Simmons

BMS cooks up schizophrenia stigma-busting push with Gail Simmons

Oct 13, 2025 11:29am

Trump Donald Trump

BMS will charge same price in UK as its does in US for Cobenfy

Sep 22, 2025 12:05pm

Teva’s CEO shares ‘Pivot to Growth’ progress

Jun 27, 2025 9:00am

Boerner

Bristol Myers CEO stays bullish on Cobenfy despite trial flop

Jun 12, 2025 12:43pm